Rhemium-186-1-hydroxyethylidene-1,1-diphosphonate ( 186 Re-HEDP) has been used for the palliation of metastatic bone pain. However, delayed blood clearance and high gastric uptake of radioactivity have been observed upon injection, due to the instability of 186 Re-HEDP. We designed, synthesized and evaluated a stable 186 Re-mercaptoacetylglycylglycylglycine (MAG3) complex-conjugated bisphosphonate, [[[[(4-hydroxy-4,4-diphosphonobutyl) 186 Re-HEDP remained intact 24 hours post-incubation. In biodistribution experiments, the radioactivity level of 186 Re-MAG3-HBP in bone was signiˆcantly higher than that of 186 Re-HEDP. Blood clearance of 186 Re-MAG3-HBP was faster than that of 186 Re-HEDP. In addition, the gastric accumulation of 186 Re-MAG3-HBP radioactivity was lower. To evaluate the therapeutic eŠects of 186 Re-MAG3-HBP, an animal model of bone metastasis was prepared. In the rats treated with 186 Re-HEDP, tumor growth was comparable to that in untreated rats. In contrast, when 186 Re-MAG3-HBP was administered, tumor growth was signiˆcantly inhibited. Bone pain was attenuated by treatment with 186 Re-MAG3-HBP or 186 Re-HEDP, but 186 Re-MAG3-HBP tended to be more eŠective. These results indicate that 186 Re-MAG3-HBP could be useful as a therapeutic agent of metastatic bone pain. Moreover, based on the similar concept, we designed, synthesized, and evaluated a 99m Tc-6-hydrazinopyridine-3-carboxylic acid-conjugated bisphosphonate ( 99m Tc-HYNIC-HBP) as a bone scintigraphic agent. 99m Tc-HYNIC-HBP gave higher levels of radioactivity in bone than 99m Tc-HMDP. There was no signiˆcant diŠerence in clearance from blood between 99m Tc-HYNIC-HBP and 99m Tc-HMDP. Consequently, 99m Tc-HYNIC-HBP showed a higher bone-to-blood ratio than 99m Tc-HMDP. Theˆndings indicate that 99m Tc-HYNIC-HBP holds great potential for bone scintigraphy.

